Wannaphut Chalothorn, Ponvilawan Ben, Kanitthamniyom Chanakarn, Danpanichkul Pojsakorn, Kulthamrongsri Narathorn, Prasitsumrit Vitchapong, Wattanachayakul Phuuwadith, Saowapa Sakditad
Department of Medicine, John A. Burns School of Medicine, University of Hawai'i - Honolulu, Honolulu, Hawaii, USA.
Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
Proc (Bayl Univ Med Cent). 2025 Jul 14;38(5):722-731. doi: 10.1080/08998280.2025.2524792. eCollection 2025.
Previous studies have demonstrated disparities in survival outcomes between Black/African American, Asian, and White patients with non-small cell lung cancer (NSCLC). Some studies have suggested that non-White patients have poorer survival outcomes due to socioeconomic factors, while others have reported different findings. Therefore, we performed a comprehensive review and meta-analysis to evaluate the impact of racial disparity on NSCLC survival outcomes.
PubMed, Ovid MEDLINE, Embase, and Google Scholar were searched for articles published until September 2024. Eligible studies with aligned research objectives were included. Two reviewers independently extracted data. Methodological quality was assessed using the Newcastle-Ottawa Scale. The meta-analysis adhered to the PRISMA guidelines.
Fifteen studies with 763,314 patients met the eligibility criteria. Asian and Asian/Pacific Islander (API) patients had significantly better overall survival (OS) compared to White patients (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.79-0.94; < 0.01 and HR, 0.80; 95% CI, 0.69-0.93; < 0.01, respectively). In contrast, OS differences were not statistically significant between Black and White (HR, 1.00; 95% CI, 0.94-1.07; < 0.01) or Hispanic and White patients (HR, 0.93; 95% CI, 0.87-1.00; = 0.19). Further, the subgroup analyses did not demonstrate any significant difference in OS outcome in any stage when comparing Black to White patients (stage I HR, 1.11; 95% CI, 1.00-1.23; < 0.01; stage II HR, 1.03; 95% CI, 0.96-1.10; = 0.26; stage III HR, 1.04; 95% CI, 0.96-1.12; < 0.01; and stage IV HR, 1.02; 95% CI, 0.97-1.07; < 0.01).
Asian and API patients with NSCLC exhibited superior OS outcomes compared to White patients. In contrast, racial disparities in survival outcomes were statistically insignificant for Black and Hispanic patients. Additionally, staging disparities in OS were not observed between Black and White patients with NSCLC.
先前的研究表明,非小细胞肺癌(NSCLC)患者中,黑人/非裔美国人、亚洲人和白人在生存结果方面存在差异。一些研究表明,非白人患者由于社会经济因素,生存结果较差,而其他研究则报告了不同的结果。因此,我们进行了一项全面的综述和荟萃分析,以评估种族差异对NSCLC生存结果的影响。
在PubMed、Ovid MEDLINE、Embase和谷歌学术上检索截至2024年9月发表的文章。纳入研究目标一致的符合条件的研究。两名评审员独立提取数据。使用纽卡斯尔-渥太华量表评估方法学质量。荟萃分析遵循PRISMA指南。
15项研究共763314名患者符合纳入标准。与白人患者相比,亚洲人和亚太岛民(API)患者的总生存期(OS)显著更好(风险比[HR],0.86;95%置信区间[CI],0.79 - 0.94;P < 0.01和HR,0.80;95% CI,0.69 - 0.93;P < 0.01)。相比之下,黑人和白人(HR,1.00;95% CI,0.94 - 1.07;P < 0.01)或西班牙裔和白人患者之间的OS差异无统计学意义(HR,0.93;95% CI,0.87 - 1.00;P = 0.19)。此外,亚组分析显示,在任何分期中,比较黑人和白人患者的OS结果均无显著差异(I期HR,1.11;95% CI,1.00 - 1.23;P < 0.01;II期HR,1.03;95% CI,0.96 - 1.10;P = 0.26;III期HR,1.04;95% CI,0.96 - 1.12;P < 0.01;IV期HR,1.02;95% CI,0.97 - 1.07;P < 0.01)。
与白人患者相比,患有NSCLC的亚洲人和API患者表现出更好的OS结果。相比之下,黑人和西班牙裔患者在生存结果方面的种族差异无统计学意义。此外,NSCLC的黑人和白人患者在OS分期方面未观察到差异。